- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03381859
Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4 (CLEAR-C4)
A Single-site, Open-label, Non-comparator Clinical Trial to eLiminate HCV-infection in Treatment-naïve, EgyptiAn Patients With End-stage Renal Disease on Renal Dialysis, With Chronic Hepatitis C Genotype 4 Infection Using a 12-week Course of Once-daily Single Oral Tablet of Elbasvir (50mg)/Grazoprevir (100 mg)
Primary Efficacy Objective
-To assess whether a 12-week treatment course with oral 50 mg elbasvir plus 100 mg grazoprevir given in a single daily dose to treatment-naïve patients with end-stage renal disease (ESRD) and infected with genotype 4 (GT4) chronic HCV (CHC) infection can produce a sustained viral response (SVR), i.e. HCV RNA below the lower limit of quantification [LLOQ] for 12 weeks (SVR12) after completion of the study treatment course
Secondary Objectives
- To assess the efficacy of elbasvir/grazoprevir in suppressing HCV viremia in treatment-naïve GT4 CHC patients at each scheduled visit and clinically meaningful endpoints (Week 2, 8 and 12 [End of Treatment - EOT]) and 24 (SVR12)
- To assess the safety and tolerability of a 12-week treatment course with elbasvir/grazoprevir in treatment-naïve patients with ESRD and infected with GT4 CHC.
- To assess liver fibrosis by non-invasive evaluation of liver stiffness (Fibroscan®) in the same patients before treatment and EOT and SVR12
Clinical hypotheses.
Primary Efficacy Hypothesis
- A 12-week treatment course with elbasvir/grazoprevir in treatment-naïve patients with ESRD and infected with GT4 CHC infection will result in an HCV RNA below the LLOQ in 95% of patients within 2 weeks of treatment, and at least 95% will have an SVR12.
Secondary hypotheses
- A 12-week treatment course with elbasvir/grazoprevir in ESRD GT4 treatment-naïve patients will result in undetectable viremia in 95% patients at Week 2, 4, 8 and 12 (EOT) and 24 (SVR12)
- Treatment will be safe and well-tolerated in these patients, as determined by the type and number of adverse events identified through laboratory testing, vital signs and physical examinations.
- In these patients with liver fibrosis before treatment, the liver fibrosis as assessed by non-invasive evaluation of liver stiffness (Fibroscan®) will improve by EOT and SVR12
Study Overview
Status
Intervention / Treatment
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Almanial
-
Cairo, Almanial, Egypt
- Kasr Alainy hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and dated informed consent obtained before undergoing any trial-related procedures
- Male and female patients; age between 21 and 70 years inclusive
- Chronic hepatitis C infection with genotype 4 confirmed by genotypic testing at screening or within 6 months of screening period
- Treatment naïve - absence of prior failed treatment for HCV with Interferon plus ribavirin therapy or directly acting antivirals (treatment experienced)
- Detectable HCV viral load (quantitative)
- Liver cirrhosis subjects may be included but will be limited to those with compensated liver disease
- Chronic kidney disease with end-stage liver disease (defined as glomerular filtration rate [eGFR] <=15 mL/min/1.73m2) on hemodialysis for at least 3 months, including individuals awaiting kidney transplant and those with failed kidney transplants but no longer on immunosuppressant therapy)
- Screening laboratory values within the defined protocol thresholds
- Women of child-bearing potential, must agree to abstinence or use of effective contraceptive methods (e.g. oral or injectable contraceptives, intra-uterine device (IUD), transdermal contraceptive patch) at least 2 weeks prior Day 1 through 14 days after the last dose of the study drug.
- Ability to communicate, participate, and comply with the requirements of the entire study
Exclusion Criteria:
- Patients didn't sign informed consent or under age of legal consent
- Pregnant or breastfeeding woman
- Has HCV genotypes other than G4
- On peritoneal dialysis for management of kidney disease
- Co-Infection with HIV and/or HBV (with positive HBsAg)
- Evidence of hepatocellular carcinoma (HCC)
- Evidence of hepatic decompensation as evidenced by presence or history of ascites, esophaegal or gastric bleeding, hepatic encelopathy or other signs of or symptoms of advanced liver disease, or cirrhotic subjects with Child-Pugh B or C, or who have a Purgh-Turcotte (CPT) score >6
- Active or suspected non-hepatic malignancy or history of any malignancy except for cured basal cell or squamous cell skin cancer or in situ cervical cancer
- Organ transplant (including hematopoietic stem cell transplant) other than kidney, cornea, and hair
- Conditions requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial
- Uncontrolled or poorly controlled hypertension
- Pregnant, breast-feeding, expecting to conceive or donate eggs, or donate sperm from Day 1 through 14 days after the last study dose.
- Significant cardiovascular disorder (e.g. myocardial infarction or unstable angina) or interventional cardiovascular procedure within 3 months prior to signing informed consent
- Recent (within 3 months prior to signing informed consent) episode or recurrence of stroke, transient ischemic attack (TIA) or neurological disorder, including but not limited to seizures
- ALT or AST > 10-fold the upper limit of normal
- Evidence of liver disease due to causes other than chronic HCV infection
- Evidence of poorly controlled diabetes (defined as HbA1c > 8%)
- History of alcohol or drug abuse within the last 12 months
- Serum albumin level < 3.0 g/dL
- INR > 1.3 N
- Total Bilirubin levels > 2.0 mg/dL unless explained by Gilbert's disease
- Platelets Count <75,000/µL
- White blood cell count < 1500 µL (mm3)
- Clinically significant TSH and T4 level poorly controlled thyroid function
- Patients with any abnormality on physical examination, vital signs (sitting systolic blood pressure greater than 150 mmHg, sitting diastolic blood pressure greater than 90 mmHg and pulse greater than 90 bpm) and ECG, unless these abnormalities are judged to be not clinically significant by the Investigator
- Body Mass Index < 18.5 or > 35 kg/m2
- Use of other investigational drugs/treatments within the previous 3 months
- Known hypersensitivity to any of the test materials or related compounds.
- Active autoimmune disease.
- History of moderate, severe or uncontrolled psychiatric disease, especially severe depression and prior suicidal attempt.
- Unable to comply with research study visits.
- Poor venous access not allowing screening laboratory collection.
- Any other condition that, in the opinion of the Investigator, may be a contraindication to study participation or jeopardize the study conduct according to the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment Arm
Patients to receive 12 weeks of Elbasvir (50mg) / Grazoprevir (100mg)
|
Hepatitis C Virus direct-acting antiviral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SVR12
Time Frame: 24 weeks from treatment initiation date
|
absence of HCV plasma RNA 12 weeks after end of treatment
|
24 weeks from treatment initiation date
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shyamasundaran Kottilil, MD, PhD, University of Maryland, College Park
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Disease Attributes
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Infections
- Communicable Diseases
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Anti-Infective Agents
- Antiviral Agents
- Grazoprevir
- Elbasvir-grazoprevir drug combination
Other Study ID Numbers
- HP-00076974
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C Virus Infection, Response to Therapy of
-
Johns Hopkins UniversityAbbVieRecruitingHepatitis C Virus Infection, Response to Therapy ofUnited States, Canada
-
National Taiwan University HospitalNational Health Research Institutes, TaiwanUnknownHepatitis C Virus Infection, Response to Therapy ofTaiwan
-
National Taiwan University HospitalRecruitingHepatitis C Virus Infection | Hemodialysis Complication | Hepatitis C Virus Infection, Response to Therapy ofTaiwan
-
University of California, San DiegoCompletedHepatitis C | Hepatitis C Virus Infection, Response to Therapy ofUnited States
-
Akros Pharma Inc.CompletedHepatitis C Virus Infection, Response to Therapy ofPuerto Rico
-
Kawin Technology Share-holding Co., Ltd.KawinGreen Biotech Co., Ltd.CompletedHepatitis C, Chronic | Hepatitis C Virus Infection, Response to Therapy ofChina
-
Egyptian Liver HospitalUnknownHepatitis C Virus Infection, Response to Therapy ofEgypt
-
Hasselt UniversityJessa Hospital; Ziekenhuis Netwerk Antwerpen (ZNA); Ziekenhuis Oost-Limburg; Algemeen... and other collaboratorsRecruitingDrug Use | Hepatitis C Virus Infection, Response to Therapy ofBelgium
-
National Taiwan University HospitalRecruitingHepatitis C Virus Infection | Hepatitis C Virus Infection, Response to Therapy of | Human Immunodeficiency Virus (HIV) CoinfectionTaiwan
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)CompletedHuman Immunodeficiency Virus | Hepatitis C Virus Infection, Response to Therapy ofUnited States
Clinical Trials on Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
-
University of Illinois at ChicagoMerck Sharp & Dohme LLCActive, not recruitingHepatitis C | Hiv | Substance Use Disorders | Coinfection, HIVUnited States
-
Azienda Ospedaliera Universitaria Policlinico Paolo...CompletedChronic HCV HepatitisItaly
-
Taichung Veterans General HospitalMerck Sharp & Dohme LLCTerminatedLiver Transplant Infection | Kidney Transplant Infection | Chronic Hepatitis cTaiwan
-
University of DundeeCompletedHepatitis CUnited Kingdom
-
Oregon Health and Science UniversityCompletedSubstance Abuse, Intravenous | Hepatitis C | Substance Use DisordersUnited States
-
King Fahad Medical CityCompletedHepatitis C, ChronicSaudi Arabia
-
Merck Sharp & Dohme LLCCompleted
-
University of PennsylvaniaMerck Sharp & Dohme LLCCompletedHepatitis C | Hemodialysis | Nosocomial InfectionUnited States
-
Fundacion Clinic per a la Recerca BiomédicaUnknownHepatitis C | HIVSpain
-
San Francisco Veterans Affairs Medical CenterMerck Sharp & Dohme LLCUnknown